NCT03853785 is a Phase 3 clinical trial of MMR vaccine in Condylomata Acuminata, sponsored by Assiut University.

Who is sponsoring NCT03853785?

NCT03853785 is sponsored by Assiut University.

What drugs are being tested in NCT03853785?

Interventions in NCT03853785: MMR vaccine, Candida antigen, Topical Podophyllin.

What condition does NCT03853785 study?

NCT03853785 studies Condylomata Acuminata.

Is NCT03853785 still recruiting?

NCT03853785 is currently status unknown. Last updated 11 March 2019.

Last reviewed 2019-03-11 · How we verify

NCT03853785

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy of Intralesional Measles, Mumps, Rubella (MMR) Vaccine, Intralesional Candidal Antigen and Topical Podophyllin in Treatment of Genital Warts: A Comparative Study

Status unknown Phase 3 Last updated 11 March 2019

What this trial tests

Phase 3 trial testing MMR vaccine in Condylomata Acuminata in 45 participants. Status unknown.

Timeline

1 February 2020

Primary endpoint
1 February 2021

1 December 2021

Quick facts

Lead sponsor	Assiut University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	1 February 2020
Primary completion	1 February 2021
Estimated completion	1 December 2021

Drugs / interventions tested

MMR vaccine — full drug profile →
Candida antigen — full drug profile →
Topical Podophyllin — full drug profile →

Conditions studied

Condylomata Acuminata — all drugs for Condylomata Acuminata →

Sponsor

Assiut University

Who can join

Adults 3 to 50, any sex, with Condylomata Acuminata. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Cure rate
Time frame: 45 days
Assess cure rate of MMR vaccine and candida antigen and topical podophyllin in treatment of genital warts (complete disappearance of lesions) in 45 days duration and compare efficacy of the measures.

Sponsor's own description

This study compares the safety and efficacy of intralesional Candidal antigen versus Intralesional MMR vaccine versus podophyllin for treatment of genital warts.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MMR vaccine

Trials testing the same drug.

NCT06806137 — A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Heal · Phase 3 · recruiting
NCT06855160 — A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rub · Phase 3 · recruiting
NCT06740630 — A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to · Phase 3 · recruiting
NCT04475081 — Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis · Phase 3 · completed
NCT03547271 — Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pedi · Phase 3 · completed

Other recruiting trials for Condylomata Acuminata

Currently open trials in the same condition.

NCT06197802 — Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women · active not recruiting
NCT05056402 — An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old · Phase 3 · active not recruiting
NCT04537156 — Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E. · Phase 3 · active not recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03853785 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 11 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03853785.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing